(Alliance News) - PureTech Health PLC on Monday said its founded entity Celea Therapeutics has announced the first dosing in a phase 3 trial. Read More
(Alliance News) - GSK reports positive Jemperli trial data, while Plus500 posts record first-half revenue. Elsewhere, Heathrow's first-half passenger traffic edged higher despite a June decline caused by weaker Middle East travel. Read More
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - PureTech Health PLC on Thursday said its founded entity Celea Therapeutics Inc has completed a USD180 million financing, which will enable the early launch of a phase 3 drug trial. Read More
(Alliance News) - PureTech Health PLC on Tuesday highlighted positive phase 1 data from Seaport Therapeutics Inc for GlyphAgo, supporting plans to advance the experimental treatment into mid-stage trials for generalised anxiety disorder. Read More
(Alliance News) - PureTech Health PLC on Friday noted the pricing of its founded entity Seaport Therapeutics Inc for its planned initial public offering on the Nasdaq. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - PureTech Health PLC on Monday said that Seaport Therapeutics Inc, founded by PureTech, had filed for an initial public offering on New York's Nasdaq Stock Market. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - PureTech Health PLC said on Friday its drug treating idiopathic pulmonary fibrosis, deupirfenidone, has been designated as an orphan drug by both the US Food & Drug Administration and the European Commission. Read More
PureTech Health PLC - Boston, Massachusetts-based biotech and pharmaceutical firm - Promotes interim Chief Executive Officer Robert Lyne to CEO on a permanent basis from Thursday. Lyne has served as interim CEO since July, having joined the company in January 2024 as chief portfolio officer. He has overseen progress across PureTech's programmes and advancing strategic and operational priorities. Lyne was previously CEO of Arix Bioscience PLC. Read More
(Alliance News) - PureTech Health PLC on Monday said its idiopathic pulmonary fibrosis drug candidate deupirfenidone has cleared a key regulatory milestone, with the US Food & Drug Administration backing progression into a pivotal phase 3 trial planned for the first half of 2026. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced in the past week and not separately reported by Alliance News: Read More
(Alliance News) - PureTech Health PLC on Thursday pledged to return to its "core strengths" as it looks to advance its current portfolio efficiently while maintaining a strong balance sheet. Read More
(Alliance News) - Stocks were called slightly higher on Thursday, with many eyes on the US' flash quarterly personal consumption expenditures data. Read More
